What is the purpose of the M-prib-2 Bortezomib 2mg Injection?
M-prib-2 Bortezomib 2mg Injection is a medicine used to treat multiple myeloma, which is a kind of bone marrow cancer. Bortezomib is also used to treat patients with mantle cell lymphoma, (fast-growing cancer that begins in the cells of the immune system). Bortezomib belongs to the class of medicines known as antineoplastic agents.
Is bortezomib a type of chemotherapy?
Velcade (bortezomib) is a targeted therapy, which is a kind of chemotherapy. Velcade is a proteasome inhibitor, which is a type of medication. The FDA has given it the approval to treat multiple myeloma and mantle cell lymphoma. Many notable clinical trials have looked into VELCADE.
What is the maximum amount of time you can take bortezomib?
If you’ve already received myeloma treatment, you can have bortezomib on its own. Bortezomib is commonly taken twice a week for two weeks. After that, you get a ten-day rest. A treatment cycle is a three-week period of treatment.
What are the M-prib-2 Bortezomib 2mg Injection side effects?
- The injection site may cause dizziness
- lack of appetite
- or pain/redness.
- Common adverse effects include nausea
- vomiting, and diarrhea.
- Your doctor may recommend medication to prevent or alleviate nausea
- vomiting, or diarrhea in some circumstances.
For more details Click Here.
Is M-prib-2 Bortezomib 2mg Injection associated with hair loss?
Hair loss is a common occurrence. Hair loss isn’t a direct side effect of Velcade, but it could be caused by other medications you’re taking with it. People using Velcade plus the cytotoxic medication cyclophosphamide, for example, may experience hair loss.
Is M-prib-2 Bortezomib 2mg Injection an oral medication?
According to findings from mid-stage research presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia, the investigational oral proteasome inhibitor MLN9708—which is a protein kinase C inhibitor—is a promising treatment option. The new version of Velcade® (bortezomib) may be more effective and well-tolerated than Velcade injections.
How frequently is M-prib-2 Bortezomib 2mg Injection administered?
Velcade is given twice weekly for the intravenous catheter, followed by a flush with sodium chloride 9 mg/ml (0.9 percent) solution for injection. wo Weeks 1–4, 8, and 11 are followed by a ten-day vacation from Days 12–21. Two further VcR-CAP cycles are advised for patients who had a response to Cycle 6. At least 72 hours should pass between successive VELCADE doses.
What is the most effective method for diluting M-prib-2?
2.5 mg/ml Bortezomib After diluting the Solution for Injection to 1 mg/ml (see section 6.6), it is given as a 3-5 second bolus a peripheral or central intravenous injection